About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduc ...

A gut microbe could naturally regulate sugar cravings and blood sugar levels, offering a promising alternative to drugs like ...

Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed.The ...

The intersection of politics and medicine shapes the trajectory of health care delivery in the United States.The Affordable ...

The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks ...

This cohort study found that key sociodemographic, health care, and clinical factors are associated with receipt of semaglutide, a ...

Ascletis Pharma has reported positive topline outcomes from its US Phase Ia single ascending dose (SAD) study of the oral ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

HOUSTON - Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotech company with a market capitalization of approximately $90 million, is expanding its investigational pipeline with the ...

Coya Therapeutics advances COYA 303 for inflammatory diseases, combining COYA 301 and GLP-1 RA for a synergistic anti-inflammatory effect.

The ability to regulate one's own food intake is essential to the survival of both humans and other animals. This innate ...